anemia
defin
world
health
organ
hemoglobin
hb
valu
gdl
adult
male
gdl
nonpregn
women
alter
efficaci
tissu
oxygen
suppli
constitut
one
main
caus
complic
mortal
hospit
admiss
prolong
hospit
stay
impair
patient
qualiti
life
ferropen
anemia
regard
preval
disord
world
affect
approxim
popul
anemia
due
chronic
diseas
acd
common
form
anemia
hospit
critic
ill
patient
account
onethird
case
anemia
elderli
individu
anemia
associ
chronic
renal
failur
secondari
erythropoietin
epo
defici
acd
erythropoiesi
inhibitor
nutrit
defici
urem
toxic
among
other
highli
preval
proport
degre
renal
dysfunct
anemia
oncolog
patient
preval
combin
characterist
acd
type
anemia
ferropen
megaloblast
myelosuppress
hemolyt
often
underdiagnos
undertr
anemia
constitut
neg
prognost
factor
advers
effect
upon
patient
qualiti
life
c
p
l
c
e
h
e
r
e
p
n
e
c
h
e
h
e
r
p
n
radiotherapi
patient
admit
critic
care
show
high
preval
anemia
import
transfus
need
underli
etiolog
multifactori
natur
allogen
blood
transfus
abt
extrem
use
treatment
anemia
viabl
option
mani
patient
howev
transfus
constitut
limit
resourc
despit
million
unit
blood
donat
year
accord
data
without
import
associ
complic
gener
object
treatment
anemia
minim
symptom
system
complic
associ
hypoxia
improv
patient
qualiti
life
surviv
physiolog
condit
distribut
proport
cardiac
output
blood
content
four
time
greater
amount
actual
consumedthu
guarante
suffici
suppli
meet
tissu
need
eve
n
u
n
e
r
c
n
e
p
h
si
olog
reservoir
hypoxia
induc
factor
molecular
cascad
activ
respons
hypoxia
coordin
rang
gene
charg
cell
tissu
modif
destin
adapt
situat
hypoxia
adapt
r
e
p
n
e
n
e
n
c
l
u
e
c
e
n
r
l
r
e
g
n
l
microcirculatori
cellular
chang
increas
tissu
extract
hemoglobin
usual
use
indic
erythrocyt
mass
releas
though
data
human
defin
hemoglobin
level
oxygen
releas
compromis
tissu
hypoxia
manifest
least
situat
chronic
anemia
base
indirect
paramet
arteri
oxygen
satur
lactat
level
transfus
trigger
threshold
normovolem
patient
without
cardiovascular
e
e
c
n
e
r
e
b
e
b
u
g
l
f
hemoglobin
research
studi
carri
quintana
et
al
involv
questionnair
spanish
icu
confirm
fundament
orient
use
hemoglobin
valu
decid
use
abt
abt
rate
though
appear
gener
agreement
transfus
indic
hemoglobin
gdl
gdl
case
patient
heart
diseas
et
al
tricc
studi
random
clinic
trial
rct
involv
normovolem
critic
patient
confirm
equival
term
complic
mortal
restrict
transfus
strategi
transfus
trigger
gdl
maintain
hb
level
gdl
versu
liber
strategi
transfus
trigger
gdl
rang
gdl
specif
restrict
strategi
allow
reduct
number
transfus
vs
red
cell
concentr
unitspati
author
also
observ
decreas
mortal
day
restrict
transfus
strategi
subgroup
patient
apacheii
score
vs
patient
year
age
vs
critic
patient
acut
ischem
event
earli
phase
sever
sepsi
could
repres
import
except
safeti
restrict
transfus
strategi
recommend
trigger
threshold
gdl
hand
increas
hemoglobin
avail
alway
associ
parallel
increas
tissu
oxygen
consumpt
revers
deleteri
effect
anemia
explan
phenomenon
may
impli
seri
factor
deplet
store
red
cell
rigid
mitochondri
dysfunct
recent
studi
question
valid
hemoglobin
univers
indic
abt
suggest
tissu
oxygen
consumpt
paramet
possibl
physiolog
indic
abt
mix
venou
satur
intracerebr
tissu
pressur
oxygen
extract
index
nearinfrar
spectroscopi
anemia
pero
exenta
de
important
complicacion
es
responsabilidad
del
conoc
sopesar
toda
la
alternativa
dispon
para
el
manejo
global
de
la
anemia
transfusion
agent
estimulador
de
la
eritropoyesi
ferroterapia
oral
endovenosa
otra
alternativa
han
de
ser
empleada
de
forma
racion
la
evidencia
dispon
hasta
la
fecha
el
present
de
resum
alguna
de
la
anemia
su
la
principal
alternativa
la
luz
de
lo
conocimiento
actual
con
especi
en
el
pacient
central
nervou
system
process
latenc
period
latenc
gastric
mucos
ph
etc
despit
univers
use
clearli
demonstr
abt
systemat
improv
tissu
oxygen
prognosi
anem
patient
studi
lealnov
et
al
prospect
anem
stabl
neurolog
trauma
patient
record
increas
brain
tissu
oxygen
brain
tissu
oxygen
partial
pressur
p
bt
hour
abt
case
prove
frequent
patient
lesser
p
bt
baselin
valu
zygun
et
al
rct
involv
patient
sever
head
injuri
confirm
increas
p
bt
case
proport
posttransfus
increas
hemoglobin
turn
pronounc
patient
lactat
pyruv
index
effect
upon
brain
metabol
date
studi
provid
firm
support
use
abt
treatment
anemia
hemodynam
stabl
critic
patient
without
evid
acut
bleed
avail
data
confirm
hemoglobin
valu
gdl
well
toler
critic
patient
without
acut
bleed
present
recommend
evalu
use
abt
accord
physiolog
paramet
hemoglobin
valu
alon
constitut
exclus
suffici
criterion
sens
napolitano
et
al
recent
publish
clinic
guid
abt
especi
orient
toward
critic
traumatolog
patient
set
author
consid
abt
clearli
indic
patient
evid
hemorrhag
shock
potenti
indic
case
acut
bleed
associ
hemodynam
instabl
insuffici
avail
oxygen
recommend
restrict
transfus
strategi
hb
gdl
stabl
anemia
patient
possibl
except
individu
myocardi
ischemia
level
recommend
investig
suggest
link
hemoglobin
patient
hemodynam
statu
durat
anemia
cardiopulmonari
paramet
indic
abt
level
recommend
lastli
guid
contempl
seri
measur
destin
reduc
need
abt
potenti
use
recombin
erythropoietin
reduct
blood
extract
number
volum
use
blood
sampl
reinfus
devic
periop
recoveri
anemia
patient
admit
intens
care
unit
highli
preval
repres
frequent
laboratori
test
alter
critic
patient
anemia
multifactori
origin
acd
periop
bleed
frequent
laboratori
test
extract
gastrointestin
bleed
coagulopathi
extracorpor
techniqu
nutrit
andor
iron
defici
hemodilut
hemolysi
drug
interfer
erythropoiesi
eg
angiotensinconvert
enzym
inhibitor
acei
acd
probabl
common
etiolog
case
defin
hb
gdl
associ
inflammatori
process
clinic
biolog
evid
creactiv
protein
mgl
ferritin
transferrin
satur
index
tsi
function
iron
defici
fid
substrat
acd
consequ
iron
retent
within
biolog
deposit
macrophag
reticuloendotheli
system
inhibit
intestin
absorpt
degrad
downregul
intestin
transport
upregul
increas
ferritin
thu
reduc
avail
bone
marrow
erythropoiesi
acd
character
coexist
inhibit
prolifer
erythroid
precursor
synthesi
bone
marrow
respons
endogen
erythropoietin
stem
cell
factor
hepcidin
hormon
proinflammatori
cytokin
tnfa
tnfg
activ
synthes
inflammatori
infecti
traumatolog
neoplast
process
regard
agent
respons
acd
fid
also
respons
immun
respons
alter
critic
patient
contribut
longer
durat
inflammatori
respons
patient
stay
poorer
prognosi
therapeut
possibl
relat
anemia
critic
patient
analyz
detail
group
follow
abt
drug
treatment
erythropoiet
stimul
iron
therapi
antifibrinolyt
hemostat
agent
autolog
blood
donat
andor
reinfus
program
restrict
individu
transfus
criteria
abt
rapid
effect
way
restor
physiolog
hemoglobin
valu
thu
increas
oxygen
transport
capac
particularli
use
context
sever
anemia
andor
activ
bleed
without
import
complic
transmiss
infecti
diseas
due
imposs
viral
detect
window
period
new
emerg
infect
risk
immunetyp
reaction
allerg
hemolyt
etc
cardiopulmonari
thromboembol
complic
infect
postop
complic
prolong
stay
increas
hospit
mortal
neoplast
recurr
revers
posterior
leukoencephalopathi
etc
potenti
complic
advers
effect
abt
must
weigh
known
increas
morbiditymort
secondari
anemia
mani
studi
suggest
increas
patient
mortal
associ
abt
number
multicent
observ
studi
report
evid
associ
dosedepend
abt
increas
morbiditymort
critic
patient
abc
studi
involv
european
icu
case
reveal
prolong
stay
increas
percentag
multiorgan
dysfunct
mortal
among
patient
administ
abt
mortal
vs
crit
studi
involv
icu
unit
state
case
turn
confirm
prolong
stay
increas
mortal
critic
care
patient
administ
abt
adjust
mortal
risk
p
howev
studi
question
increas
mortal
associ
abt
critic
patient
soap
studi
involv
european
icu
case
multivari
analysi
reveal
associ
abt
poorer
prognosi
rr
recent
metaanalysi
conduct
marik
et
al
compris
studi
patient
confirm
abt
independ
predictor
mortal
nosocomi
infect
acut
respiratori
distress
patient
risk
likewis
retrospect
studi
publish
khorana
et
al
multicent
patient
admit
hospit
due
neoplast
diseas
confirm
signific
increment
n
h
e
r
k
f
e
v
e
l
p
n
g
v
e
n
u
n
r
e
r
l
thromboembol
hospit
mortal
patient
administ
abt
risk
blood
transmiss
pathogen
decreas
drastic
last
decad
thank
introduct
nucleic
acid
amplif
techniqu
screen
method
microorgan
potenti
transmit
abt
includ
virus
hbv
estim
risk
hcv
risk
hiv
risk
hav
parvoviru
hltv
cmv
ebv
west
nile
viru
simian
foami
viru
dengu
viru
enteroviru
coronaviru
prion
bacteria
treponema
pallidum
genera
staphylococcu
pseudomona
yersinia
borrelia
serratia
enterobact
protozoa
gener
leishmania
trypanosoma
plasmodium
toxoplasma
babesia
incid
clinic
sepsi
secondari
abt
estim
transfus
repres
death
attribut
abt
unit
state
likewis
persist
risk
blood
transmiss
still
unknown
virus
virus
experienc
geograph
expans
chikungunya
viru
st
loui
enceph
viru
e
c
n
f
n
e
w
v
r
n
f
c
r
e
u
z
f
e
l
j
c
b
diseas
noninfecti
complic
associ
abt
noninfecti
complic
constitut
frequent
group
advers
effect
follow
abt
among
immun
reaction
mention
made
follow
hemolyt
reaction
febril
reaction
allerg
reaction
posttransfusion
purpura
graftversushost
reaction
alloimmun
transfusionrel
acut
lung
injuri
trali
transfusionrel
immun
modul
trim
regard
nonimmun
complic
mention
made
transfus
error
iron
overload
metabol
imbal
transfusionassoci
circulatori
overload
taco
error
administ
blood
compon
head
list
noninfecti
complic
associ
abt
shot
seriou
hazard
transfus
report
th
annual
edit
regist
event
case
relat
transfus
error
follow
decreas
order
frequenc
acut
allerg
reaction
antid
immunoglobulin
relat
event
hemolyt
reaction
transfus
error
rate
would
case
per
compon
incompat
abo
classif
transfus
rate
posttransfus
allerg
reaction
show
extrem
variabl
preval
urticariform
present
anaphylactoid
form
broad
rang
associ
sign
symptom
rest
noninfecti
mechan
wherebi
abt
increas
complic
mortal
vari
though
mention
made
transfusionrel
acut
lung
injuri
trali
transfusionrel
immun
modul
trim
transfusionassoci
circulatori
overload
taco
microcirculatori
alter
though
alway
possibl
individu
concret
contribut
made
trali
seriou
advers
effect
uncertain
etiolog
one
main
sourc
f
p
r
n
f
u
n
r
g
e
n
e
f
r
e
q
u
e
n
l
underdiagnos
trali
present
regard
common
seriou
complic
associ
abt
repres
main
caus
abtrel
death
unit
state
follow
hemolyt
reaction
sepsi
character
acut
lung
damag
associ
bilater
noncardiogen
lung
edema
hypoxemia
dyspnea
tachypnea
cyanosi
hypotens
fever
trali
appear
first
hour
abt
may
regard
particular
form
acut
respiratori
distress
syndrom
antihla
antigranulocyt
antibodi
reactiv
lipid
cytokin
donor
particularli
femal
donor
target
recipi
leukocyt
propos
etiolog
agent
stimul
releas
oxidas
inflammatori
mediat
complement
alter
permeabl
integr
pulmonari
microcircul
trigger
trali
effect
estim
incid
transfus
associ
global
mortal
condit
requir
conserv
manag
oxygen
intraven
fluid
therapi
occasion
mechan
ventil
invas
maneuv
transfusionrel
immun
modul
trim
character
immunosuppress
state
link
abt
associ
observ
studi
increas
incid
pneumonia
urinari
infect
mediastin
sepsi
postop
infect
reactiv
latent
virus
oncolog
surgeri
increas
tumor
recurr
vasoact
substanc
releas
transfus
leukocyt
lymphocyt
could
respons
immun
modul
effect
associ
downregul
cellular
immun
dysfunct
natur
killer
nk
cell
cell
antigenpres
cell
apc
etc
upregul
humor
immun
although
conclus
data
indic
reduct
rate
infect
complic
mortal
neoplast
recurr
leukocyt
deplet
abt
except
heart
surgeri
reduct
shortterm
mortal
document
univers
leukocyt
deplet
practic
total
elimin
leukocyt
allogen
blood
compon
use
specif
filter
implement
european
union
sinc
spain
prolong
storag
red
cell
concentr
bag
storag
damag
may
impli
morpholog
membran
alter
loss
elast
deform
capac
function
deterior
reduct
nitric
oxid
atp
erythrocyt
deleteri
effect
upon
h
l
f
l
f
e
x
g
e
n
f
f
n
n
c
p
c
f
v
r
vasoconstrict
endotheli
damag
tissu
ischemia
presum
infect
number
observ
studi
evidenc
associ
abt
store
week
appear
postop
complic
prolong
hospit
stay
andor
increas
shortand
longterm
mortal
varieti
substanc
present
high
concentr
store
red
cell
bag
histamin
cation
eosinophil
protein
myeloperoxidas
lipid
etc
may
act
immun
regul
contribut
develop
immun
suppress
trali
tissu
damag
turn
transfusionassoci
circulatori
overload
taco
secondari
alter
alveolocapillari
hydrostat
pressur
gradient
consequ
volum
overload
estim
incid
involv
broad
rang
symptom
patient
cardiopulmonari
diseas
renal
failur
children
particularli
vulner
taco
recoveri
hemoglobin
level
mean
abt
would
contribut
clinic
improv
patient
reduct
complic
mortal
mani
case
avoid
unnecessari
transfus
administr
iron
via
oral
parenter
rout
use
erythropoiesi
stimul
agent
esa
two
wide
use
effect
pharmacolog
altern
abt
likewis
preoper
autolog
donat
program
use
antifibrinolyt
hemostat
agent
abl
effect
reduc
need
abt
mani
surgic
disciplin
associ
adjuv
esa
andor
iron
therapi
human
erythropoietin
epo
acid
polypeptid
mainli
synthes
peritubular
cell
renal
interstiti
compart
respons
drop
hematocrit
hypoxemia
andor
increas
oxygen
affin
hemoglobin
genic
express
epo
regul
multipl
transcript
factor
includ
hypoxiainduc
factor
pathway
activ
respons
hypoxia
epo
princip
bone
marrow
erythropoiesi
regul
hormon
differ
type
recombin
exogen
epo
rhuepo
darbepoetinalpha
methoxypolyethlyeneglycolbeta
cera
continu
erythropoiet
receptor
activ
constitut
main
esa
avail
market
administr
rhuepo
introduc
earli
clearli
demonstr
efficaci
treatment
anemia
patient
nephrolog
oncolog
hematolog
liver
diseas
acd
anemia
associ
treatment
aid
anemia
prematur
infant
elect
major
orthoped
cardiovascular
digest
gynecolog
surgeri
c
n
e
x
f
p
e
r
p
e
r
v
e
r
u
l
g
u
n
program
follow
administr
subcutan
intraven
esa
mimic
effect
endogen
epo
stimul
erythropoiesi
inhibit
apoptosi
erythroid
precursor
promot
prolifer
matur
clinic
respons
treatment
manifest
increas
reticulocyt
count
within
day
rise
erythrocyt
count
within
week
intens
respons
depend
esa
dose
concomit
inflammatori
andor
system
disord
avail
substrat
essenti
erythropoiesi
iron
vitamin
b
folic
acid
howev
use
agent
expens
without
import
complic
arteri
hypertens
thromboembol
hyperkalemia
headach
red
cell
aplasia
skin
rash
influenza
symptom
possibl
tumor
progress
shorten
surviv
neoplast
patient
enrol
esa
program
hemoglobin
target
gdl
exacerb
diabet
retinopathi
etc
treatment
requir
care
adjust
administ
dose
spain
type
esa
current
avail
epoetinalpha
epoetinbeta
epoetindelta
epoetinzeta
darbepoetinalpha
cera
differ
composit
receptor
affin
halflif
altern
form
present
epo
investig
inhalatori
intramuscular
rout
new
complex
modif
epo
molecul
gene
therapi
fusion
protein
hypoxiainduc
factor
stabil
mimet
substanc
hematid
constitut
futur
line
research
treatment
erythropoiet
stimul
despit
qualit
quantit
decreas
erythropoiesi
critic
patient
bone
marrow
abl
respond
administr
esa
howev
data
avail
use
esa
critic
patient
contradictori
first
rct
use
esa
critic
patient
corwin
et
al
silver
et
al
reveal
signific
decreas
transfus
need
patient
treat
esa
differ
term
morbid
mortal
recent
corwin
et
al
multicent
clinic
trial
critic
patient
show
administr
epoetinalpha
iuweek
associ
iron
reduc
transfus
need
mortal
except
subgroup
trauma
patient
receiv
esa
adjust
mortal
risk
day
metaanalysi
conduct
zarychanski
et
al
use
rhuepo
critic
patient
epoetinalpha
mainli
dose
iu
week
evidenc
small
reduct
number
transfus
respect
control
group
save
unitspati
impact
upon
mortal
hospit
stay
stay
icu
need
mechan
ventil
author
therefor
recommend
routin
use
esa
critic
patient
possibl
care
patient
select
fundament
use
coadjuv
treatment
might
optim
treatment
esa
critic
patient
still
without
technic
indic
eortc
european
organ
research
treatment
cancer
seom
spanish
societi
clinic
oncolog
guid
use
esa
anemia
neoplast
patient
confirm
efficaci
increas
hemoglobin
level
reduc
need
transfus
improv
patient
qualiti
life
though
without
consist
data
confirm
improv
patient
surviv
local
tumor
control
time
diseas
progress
diseasefre
interv
hand
sever
recent
studi
review
best
enhanc
amgen
trial
evidenc
signific
increas
venou
thromboembol
locoregion
tumor
progress
cardiovascular
mortal
patient
differ
neoplasm
subject
esa
therapi
hemoglobin
target
gdl
result
differ
healthcar
author
recommend
caution
use
agent
advis
hemoglobin
monitor
precis
adjust
esa
dose
order
abl
avoid
need
abt
recommend
year
american
societi
clinic
oncolog
asco
american
societi
hematolog
ash
esa
use
oncolog
patient
anemia
associ
chemotherapi
includ
start
treatment
subcutan
esa
event
hemoglobin
valu
gdl
monitor
iron
deposit
administr
iron
supplement
valu
gdl
establish
hemoglobin
target
concentr
scientif
societi
disadvis
esa
use
anem
neoplast
patient
without
concomit
chemotherapi
similarli
sever
studi
choir
creat
evidenc
rise
cardiovascular
complic
global
mortal
among
patient
chronic
renal
failur
subject
esa
therapi
hemoglobin
target
gdl
committe
human
medicin
product
chmp
european
medicin
evalu
agenc
emea
recommend
esa
use
manag
symptomat
anemia
nephrolog
neoplast
patient
reach
maintain
maximum
hemoglobin
concentr
gdl
administr
oral
iron
supplement
least
invas
method
restor
bodi
iron
deposit
differ
iron
salt
avail
market
tabl
show
minim
differ
term
absorpt
contain
variabl
amount
miner
iron
main
disadvantag
oral
iron
supplement
high
incid
associ
gastrointestin
side
effect
case
form
abdomin
pain
heartburn
nausea
vomit
constip
diarrhea
treatment
noncompli
rate
efficaci
treatment
depend
degre
absorpt
turn
condit
amount
posolog
condit
biolog
deposit
erythropoiet
activ
intralumin
factor
interfer
absorpt
product
oral
absorpt
iron
often
unabl
compens
continu
loss
due
effect
hepcidin
hormon
key
regul
iron
metabol
intestin
absorpt
mobil
iron
deposit
macrophag
reticuloendotheli
system
intens
inhibit
presenc
acd
thu
justifi
inefficaci
oral
iron
therapi
situat
need
often
resort
altern
administr
rout
parenter
iron
associ
esa
treatment
oral
iron
mgkgday
mgday
increas
hemoglobin
level
start
first
second
week
therapi
normal
within
month
necessari
prolong
treatment
sever
month
month
order
fill
biolog
deposit
contrast
intraven
iron
allow
faster
bone
marrow
respons
fill
deposit
week
sinc
parenter
iron
administr
becom
key
element
treatment
patient
chronic
renal
failur
enrol
renal
replac
program
compar
oral
iron
therapi
associ
esa
intraven
iron
superior
term
correct
anemia
renal
neoplast
acd
periop
origin
make
possibl
delay
reduc
esa
dose
requir
synerg
interdepend
base
requir
adequ
iron
deposit
maintain
transferrin
satur
need
erythropoiesi
hyperstimul
esa
treatment
optimum
safeti
profil
preval
seriou
advers
effect
case
per
million
dose
contrast
efficaci
defin
current
parenter
iron
formul
option
enorm
potenti
transfus
medicin
repres
extrem
use
altern
abt
global
intraven
iron
effect
predict
better
toler
abl
quickli
improv
patient
qualiti
life
compar
oral
iron
supplement
function
iron
defici
fid
characterist
acd
respond
satisfactorili
parenter
iron
administr
number
parenter
iron
formul
avail
market
tabl
differ
term
physicochem
characterist
dose
regimen
present
allow
highdos
intraven
iron
dose
mgdose
monodos
administr
total
dose
infus
thu
simplifi
posolog
reduct
number
dose
stay
acceler
restor
iron
deposit
erythropoiesi
present
indic
intraven
iron
taken
follow
intoler
noncompli
inefficaci
imposs
oral
iron
therapi
malabsorpt
disord
inflammatori
bowel
diseas
fid
need
immedi
iron
replac
effect
erythropoiesi
periop
anemia
concomit
esa
therapi
autolog
donat
program
anemia
associ
neoplasm
chemotherapi
patient
receiv
renal
replac
therapi
anemia
associ
pregnanc
puerperium
critic
patient
present
fid
prove
difficult
correct
oral
iron
therapi
inadequ
erythropoiesi
immun
alter
associ
fid
benefit
administr
parenter
iron
thu
contribut
lessen
transfus
need
potenti
also
shorten
patient
stay
well
reduc
inflammatori
paramet
patient
morbid
mortal
although
risk
benefit
ratio
clearli
establish
studi
publish
van
iperen
et
al
evidenc
tendenc
toward
lessen
transfus
need
inflammatori
respons
mortal
critic
patient
anemia
administ
intraven
iron
saccharos
alon
combin
esa
georgopoulo
advanc
knowledg
physiopatholog
anemia
due
chronic
diseas
acd
made
possibl
develop
new
treatment
modal
use
antagonist
hepcidin
inflammatori
mediat
well
hormon
cytokin
stimul
erythropoiesi
repres
possibl
interest
futur
strategi
manag
anemia
surgic
set
apart
autolog
donat
program
cell
saver
system
antifibrinolyt
hemostat
agent
manag
periop
bleed
reduc
need
transfus
aprotinin
desmopressin
acid
tranexam
acid
demonstr
efficaci
heart
digest
orthoped
surgeri
among
other
aprotinin
exert
antifibrinolyt
action
base
inhibit
key
enzym
involv
fibrinolysi
inflammatori
cascad
despit
demonstr
efficaci
heart
surgeri
surgic
specialti
market
suspend
result
multicent
rct
evidenc
increas
mortal
among
heart
surgeri
patient
receiv
aprotinin
desmopressin
antidiuret
hormon
analog
exert
hemostat
effect
increas
plasma
concentr
factor
viii
von
willebrand
factor
platelet
adhes
possibl
benefit
critic
patient
establish
turn
acid
tranexam
acid
exert
antifibrinolyt
action
inhibit
plasmin
plasminogen
activ
tranexam
acid
offer
longer
action
time
potent
demonstr
efficaci
reduc
blood
loss
need
transfus
surgic
set
studi
multicent
rct
current
ongo
assess
effect
tranexam
acid
trauma
patient
risk
suffer
signific
b
l
e
e
n
g
n
e
r
f
r
l
n
r
n
f
u
n
requir
lastli
artifici
oxygen
transport
solut
fluorocarbon
emuls
artifici
hemoglobin
solut
constitut
promis
line
research
blood
replac
therapi
though
promis
initi
result
moder
recent
studi
rais
doubt
safeti
advers
effect
clinic
efficaci
conclus
anemia
extrem
frequent
patient
disciplin
particularli
critic
ill
individu
requir
multidisciplinari
approach
ration
individu
use
avail
therapeut
resourc
allogen
blood
transfus
abt
rapid
effect
option
correct
anemia
without
import
complic
controversi
abt
must
indic
individu
basi
depend
seri
physiolog
paramet
exist
low
hemoglobin
concentr
use
pharmacolog
altern
esa
iron
therapi
antifibrinolyt
hemostat
agent
reduct
laboratori
test
number
volum
autolog
donat
program
blood
reinfus
protocol
adopt
restrict
transfus
strategi
offer
signific
reduct
blood
transfus
demand
contribut
ration
safe
effici
use
abt
